Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1201-1220 of 1,694 trials

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Gastroenteropancreatic Neuroendocrine Tumors: New Liver Treatment

We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Prostate Cancer: Enzalutamide Study

We are investigating how Enzalutamide affects molecular changes in men with localized prostate cancer before and after surgery. This study may help us understand its impact on cell growth and gene activity.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Relapsed or Refractory Tumors: AcSé-ESMART Trial

We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.

Pediatric Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Post-Surgery Pain Management: Ropivacaine Concentration Study

We are investigating whether different concentrations of ropivacaine can help reduce pain after volar plate surgery. This study aims to see if higher doses lead to less rebound pain and better overall pain control.

Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngologyPsychiatry

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology

Chronic Lymphocytic Leukemia: Ibrutinib and Obinutuzumab Treatment

We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Vitamin D for Low Testosterone in Men with Type 2 Diabetes

We are studying whether vitamin D supplements can help increase testosterone levels in men with type 2 diabetes. This trial compares the effects of vitamin D to a placebo.

Type 2 Diabetes≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesEndocrinologyInternal Medicine

Ensifentrine for Non-Cystic Fibrosis Bronchiectasis

We are studying whether nebulized ensifentrine can help reduce lung flare-ups in people with non-cystic fibrosis bronchiectasis. The trial also examines its impact on respiratory symptoms and overall quality of life.

Non-Cystic Fibrosis Bronchiectasis>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

CRN04894 for Hormonal Imbalance

We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Advanced Soft-Tissue Sarcomas: Next-Generation Sequencing Study

We are exploring whether high-throughput molecular analysis can help guide treatment for patients with advanced soft-tissue sarcomas. This study will compare treatment outcomes for those receiving NGS-guided therapy versus standard care.

Unresectable Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

MDS and AML: Venetoclax with Azacitidine

We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.

Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Gastric Cancer: IP Paclitaxel and Systemic Therapy Study

We are comparing the effects of intraperitoneal paclitaxel combined with standard therapy against standard therapy alone in patients with gastric cancer and peritoneal metastases. This study aims to see if the combination improves survival and quality of life.

Metastatic Gastric Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Irritable Bowel Syndrome: MYRRHINIL-INTEST®

We are investigating whether MYRRHINIL-INTEST® is effective and safe for people with diarrhoea-dominant and mixed-type irritable bowel syndrome. This study compares it to a placebo to see how well it works.

Diarrhea Predominant Irritable Bowel Syndrome≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Short Course Antibiotics for Gram-Negative Bacteremia

We are studying whether a 5-day antibiotic treatment is as effective and safe as longer treatments for hospitalized adults with Gram-negative bacteremia from urinary tract infections.

Gram-negative Bacteremia3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Staphylococcus Aureus Bloodstream Infections: Dalbavancin Study

We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.

Catheter-Related Bloodstream Infections3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Avapritinib: Continued Access for Previous Study Participants

We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.

Systemic Mastocytosis6-12 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology